Plerixafor

John F. DiPersio; Geoffrey L. Uy; Uma Yasothan; Peter Kirkpatrick

doi:10.1038/nrd2819

Plerixafor

John F. DiPersio, Geoffrey L. Uy, Uma Yasothan, Peter Kirkpatrick

Research output: Contribution to journal › Article › peer-review

103 Scopus citations

Abstract

In December 2008, plerixafor (Mozobil; Genzyme), an antagonist of the CXCR4 chemokine receptor, was approved by the US FDA for use in combination with granulocyte colony-stimulating factor to mobilize haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.

Original language	English
Pages (from-to)	105-107
Number of pages	3
Journal	Nature Reviews Drug Discovery
Volume	8
Issue number	2
DOIs	https://doi.org/10.1038/nrd2819
State	Published - 2009

Access to Document

10.1038/nrd2819

Cite this

@article{413cf23b72094341a55b482b50f7a477,

title = "Plerixafor",

abstract = "In December 2008, plerixafor (Mozobil; Genzyme), an antagonist of the CXCR4 chemokine receptor, was approved by the US FDA for use in combination with granulocyte colony-stimulating factor to mobilize haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.",

author = "DiPersio, {John F.} and Uy, {Geoffrey L.} and Uma Yasothan and Peter Kirkpatrick",

year = "2009",

doi = "10.1038/nrd2819",

language = "English",

volume = "8",

pages = "105--107",

journal = "Nature Reviews Drug Discovery",

issn = "1474-1776",

number = "2",

}

TY - JOUR

T1 - Plerixafor

AU - DiPersio, John F.

AU - Uy, Geoffrey L.

AU - Yasothan, Uma

AU - Kirkpatrick, Peter

PY - 2009

Y1 - 2009

N2 - In December 2008, plerixafor (Mozobil; Genzyme), an antagonist of the CXCR4 chemokine receptor, was approved by the US FDA for use in combination with granulocyte colony-stimulating factor to mobilize haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.

AB - In December 2008, plerixafor (Mozobil; Genzyme), an antagonist of the CXCR4 chemokine receptor, was approved by the US FDA for use in combination with granulocyte colony-stimulating factor to mobilize haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.

UR - http://www.scopus.com/inward/record.url?scp=59349085516&partnerID=8YFLogxK

U2 - 10.1038/nrd2819

DO - 10.1038/nrd2819

M3 - Article

C2 - 19180104

AN - SCOPUS:59349085516

SN - 1474-1776

VL - 8

SP - 105

EP - 107

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

IS - 2

ER -

Plerixafor

Abstract

Access to Document

Other files and links

Fingerprint

Cite this